These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36343223)

  • 1. Dietary Patterns and Risk of Gleason Grade Progression among Men on Active Surveillance for Prostate Cancer: Results from the Canary Prostate Active Surveillance Study.
    Schenk JM; Liu M; Neuhouser ML; Newcomb LF; Zheng Y; Zhu K; Brooks JD; Carroll PR; Dash A; Ellis WJ; Filson CP; Gleave ME; Liss M; Martin FM; Morgan TM; Wagner AA; Lin DW
    Nutr Cancer; 2023; 75(2):618-626. PubMed ID: 36343223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study.
    Schenk JM; Newcomb LF; Zheng Y; Faino AV; Zhu K; Nyame YA; Brooks JD; Carroll PR; Cooperberg MR; Dash A; Filson CP; Gleave ME; Liss M; Martin FM; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Lin DW
    J Urol; 2020 Apr; 203(4):727-733. PubMed ID: 31651227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study.
    Kearns JT; Faino AV; Newcomb LF; Brooks JD; Carroll PR; Dash A; Ellis WJ; Fabrizio M; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Zheng Y; Lin DW
    Eur Urol; 2018 May; 73(5):706-712. PubMed ID: 29433973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers.
    Bokhorst LP; Alberts AR; Rannikko A; Valdagni R; Pickles T; Kakehi Y; Bangma CH; Roobol MJ;
    Eur Urol; 2015 Nov; 68(5):814-21. PubMed ID: 26138043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using Competing Risk of Mortality to Inform the Transition from Prostate Cancer Active Surveillance to Watchful Waiting.
    Huang MM; Alam R; Gabrielson AT; Su ZT; Kassiri B; Fletcher SA; Biles MJ; Patel HD; Pavlovich CP; Schwen ZR
    Eur Urol Focus; 2022 Sep; 8(5):1141-1150. PubMed ID: 34344628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study.
    Macleod LC; Ellis WJ; Newcomb LF; Zheng Y; Brooks JD; Carroll PR; Gleave ME; Lance RS; Nelson PS; Thompson IM; Wagner AA; Wei JT; Lin DW
    J Urol; 2017 Apr; 197(4):1026-1033. PubMed ID: 27810448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence to the Mediterranean diet and grade group progression in localized prostate cancer: An active surveillance cohort.
    Gregg JR; Zhang X; Chapin BF; Ward JF; Kim J; Davis JW; Daniel CR
    Cancer; 2021 Mar; 127(5):720-728. PubMed ID: 33411364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.
    Cooperberg MR; Brooks JD; Faino AV; Newcomb LF; Kearns JT; Carroll PR; Dash A; Etzioni R; Fabrizio MD; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Lin DW; Zheng Y
    Eur Urol; 2018 Aug; 74(2):211-217. PubMed ID: 29433975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort.
    Tosoian JJ; Mamawala M; Epstein JI; Landis P; Macura KJ; Simopoulos DN; Carter HB; Gorin MA
    Eur Urol; 2020 Jun; 77(6):675-682. PubMed ID: 31918957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability.
    Cooperberg MR; Zheng Y; Faino AV; Newcomb LF; Zhu K; Cowan JE; Brooks JD; Dash A; Gleave ME; Martin F; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Carroll PR; Lin DW
    JAMA Oncol; 2020 Oct; 6(10):e203187. PubMed ID: 32852532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort.
    Newcomb LF; Thompson IM; Boyer HD; Brooks JD; Carroll PR; Cooperberg MR; Dash A; Ellis WJ; Fazli L; Feng Z; Gleave ME; Kunju P; Lance RS; McKenney JK; Meng MV; Nicolas MM; Sanda MG; Simko J; So A; Tretiakova MS; Troyer DA; True LD; Vakar-Lopez F; Virgin J; Wagner AA; Wei JT; Zheng Y; Nelson PS; Lin DW;
    J Urol; 2016 Feb; 195(2):313-20. PubMed ID: 26327354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stability of a 17-Gene Genomic Prostate Score in Serial Testing of Men on Active Surveillance for Early Stage Prostate Cancer.
    Cedars BE; Washington SL; Cowan JE; Leapman M; Tenggara I; Chan JM; Cooperberg MR; Carroll PR
    J Urol; 2019 Oct; 202(4):696-701. PubMed ID: 30958742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Older Age Predicts Biopsy and Radical Prostatectomy Grade Reclassification to Aggressive Prostate Cancer in Men on Active Surveillance.
    Druskin SC; Mamawala M; Tosoian JJ; Epstein JI; Pavlovich CP; Carter HB; Trock BJ
    J Urol; 2019 Jan; 201(1):98-104. PubMed ID: 30114397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diet quality and Gleason grade progression among localised prostate cancer patients on active surveillance.
    Gregg JR; Zheng J; Lopez DS; Reichard C; Browman G; Chapin B; Kim J; Davis J; Daniel CR
    Br J Cancer; 2019 Feb; 120(4):466-471. PubMed ID: 30679782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum prostate-specific antigen (PSA) concentration is positively associated with rate of disease reclassification on subsequent active surveillance prostate biopsy in men with low PSA density.
    Umbehr MH; Platz EA; Peskoe SB; Bhavsar NA; Epstein JI; Landis P; Partin AW; Carter HB
    BJU Int; 2014 Apr; 113(4):561-7. PubMed ID: 23746233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diet Quality, Dietary Inflammatory Potential, and Risk of Prostate Cancer Grade Reclassification.
    Su ZT; Mamawala M; Landis PK; de la Calle CM; Shivappa N; Wirth M; Hébert JR; Pavlovich CP; Trock BJ
    JAMA Oncol; 2024 Oct; ():. PubMed ID: 39418052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study.
    Lin DW; Newcomb LF; Brown MD; Sjoberg DD; Dong Y; Brooks JD; Carroll PR; Cooperberg M; Dash A; Ellis WJ; Fabrizio M; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Zheng Y;
    Eur Urol; 2017 Sep; 72(3):448-454. PubMed ID: 27889277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Initial Gleason Grade on Outcomes during Active Surveillance for Prostate Cancer.
    Masic S; Cowan JE; Washington SL; Nguyen HG; Shinohara K; Cooperberg MR; Carroll PR
    Eur Urol Oncol; 2018 Oct; 1(5):386-394. PubMed ID: 31158077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts.
    Drost FH; Nieboer D; Morgan TM; Carroll PR; Roobol MJ;
    Eur Urol; 2019 Nov; 76(5):693-702. PubMed ID: 31451332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guy's and St Thomas NHS Foundation active surveillance prostate cancer cohort: a characterisation of a prostate cancer active surveillance database.
    Shah S; Beckmann K; Van Hemelrijck M; Challacombe B; Popert R; Dasgupta P; Rusere J; Zisengwe G; Elhage O; Santaolalla A
    BMC Cancer; 2021 May; 21(1):573. PubMed ID: 34011308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.